Clinical trials: Rectum Carcinoma
Rectal Cancer
The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer
Comparative analysis of the clinical efficacy between primary Total Mesorectal Excision (TME) surgery and neoadjuvant chemotherapy combined with TME surgery for low-risk locally advanced rectal cancer.
- Trial name
- TaLaR-02 (NCT05984485)
- Testing
- neoadjuvant chemotherapy plus total mesorectal excision, total mesorectal excision
- Where
- 6 sites in China
- Volunteers
- 766 people
- Sponsor
- Sun Yat-sen University
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
- Trial name
- NCT06607185
- Testing
- LY4066434., Cetuximab, Nab paclitaxel
- Where
- 45 sites in United States, Belgium and 6 more
- Volunteers
- 750 people
- Sponsor
- Eli Lilly and Company
Rectal Cancer, Defect of Floor of Lesser Pelvis
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
The trial compares two different techniques for reconstruction of the lesser pelvic floor after an extended abdominoperineal excision for locally advanced rectal cancer.
- Trial name
- NEAPE (NCT01347697)
- Testing
- Reconstruction with an acellular porcine dermal collagen implant (biological mesh), Reconstruction with a gluteus maximus myocutaneous flap
- Where
- 8 sites in Finland, Sweden
- Volunteers
- 91 people
- Sponsor
- Umeå University
Rectal Cancer
Dosimetric Limitation of Pelvic Bone and Peritoneal Space in Rectal Cancer Patients During Chemoradiotherapy
This project first retrospectively analyzes the intestinal dose indicators related to the concurrent radiotherapy and chemotherapy of rectal cancer and gastrointestinal toxicity, and the pelvic dose indicators related to…
- Trial name
- NCT05688033
- Testing
- dosimetric limitation of pelvic bone and peritoneal space during radiotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Colorectal Cancer
Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00280176
- Testing
- bortezomib, fluorouracil, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Rectal Cancer
Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery
Patients with rectal adenocarcinoma of intermediate risk (defined by magnetic resonance imaging [MRI]), without mutations in KRAS, BRAF, NRAS and PI3KCA, who are candidates for preoperative treatment, will receive a preoperative…
- Trial name
- PIER (NCT03000374)
- Testing
- Panitumumab, 5Fluorouracil, Oxaliplatin
- Where
- 11 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Rectal Cancer
Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer (LARC): a Multicenter, Two-arm Parallel, Open-label, Randomised Phase III Trial (NeoCaCRT-III)
The goal of this clinical trial is to learn if neoadjuvant short-course radiation (SCRT) followed by 6 cycles of cadonilimab plus mFOLFOX6 works to treat patients with locally advanced rectal cancer (LARC).
- Trial name
- NeoCaCRT-III (NCT06832917)
- Testing
- AK104 plus, Chemo only
- Volunteers
- 238 people
- Sponsor
- Wan He
Recurrent Colon Cancer, Recurrent Rectal Cancer
Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer
This phase II trial is studying dasatinib to see how well it works in treating patients with previously treated metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Trial name
- NCT00504153
- Testing
- dasatinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer, Radiotherapy
Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer
This is a open-label, single-arm study to investigate the safety and efficacy of consolidative chemotherapy with camrelizumab, an anti-PD-1 antibody drug following short course radiotherapy and subsequent surgical therapy in…
- Conditions
- Rectal Cancer, Radiotherapy, Immunotherapy
- Trial name
- NCT04231552
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Cancer, Colo-rectal Cancer
Early Discharge After Colorectal Surgery
RECUPERA-C is a prospective observational pilot study evaluating the feasibility and safety of an early discharge strategy within 48 hours after minimally invasive colorectal surgery.
- Trial name
- RECUPERA-C (NCT07827378)
- Volunteers
- 97 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Rectal Cancer
Action of Synbiotics on Irradiated GI Mucosa in Rectal Cancer Treatment
The aim of this study is to investigate how bacteria and fibre interact with the epithelial cells of the gastrointestinal mucosa to reduce inflammation and to diminish tissue damage caused by radiation therapy to patients…
- Trial name
- FIPIREX (NCT03420443)
- Testing
- Oat bran, Oat bran and blueberry husks, No oral supplementation
- Volunteers
- 30 people
- Sponsor
- Region Skane
Rectal Neoplasms
Fish Oil Supplement in Rectal Cancer
Neoadjuvant treatment with radiotherapy (RDT) and chemotherapy (CT) are the treatment of choice for rectal adenocarcinomas in stages II and III. This results currently in pathologic complete response in 10% to 30% of cases.
- Trial name
- NCT02534389
- Testing
- omega-3 fish oil
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- AC Camargo Cancer Center
Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer
This phase I trial studies the side effects and the best dose of lenalidomide when given together with cetuximab in treating patients with colorectal cancer or head and neck cancer that has spread to other places in the body and…
- Conditions
- Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma
- Trial name
- ADCC (NCT01254617)
- Testing
- Cetuximab, Laboratory Biomarker Analysis, Lenalidomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Colon Cancer, Recurrent Rectal Cancer
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
This phase II trial is studying how well giving sorafenib together with bevacizumab works in treating patients with metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Trial name
- NCT00826540
- Testing
- sorafenib tosylate, bevacizumab
- Where
- 211 sites in United States
- Volunteers
- 83 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer of Rectum
Immunotherapy in Patients With Early dMMR Rectal Cancer
The purpose of this investigator-initiated, multicenter phase II trial is to evaluate the efficacy and tolerability of nivolumab and ipilimumab in patients with stage 1-3 MSI/dMMR rectal cancer.
- Trial name
- RESET-R (NCT05732389)
- Testing
- Nivolumab, Ipilimumab
- Where
- 5 sites in Denmark
- Volunteers
- 39 people
- Sponsor
- Odense University Hospital
Colorectal Cancer
Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to compare the effectiveness of two different regimens of Ro 31-7453 in…
- Trial name
- NCT00016250
- Testing
- MKC-1
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rectal Neoplasms
Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma
The investigators propose to conduct a randomised study on cT2, cT3a-b tumours less than 5 cm using two different techniques of radiotherapy boost following neoadjuvant chemoradiotherapy (nCRT) (CAP45): EBRT (9 Gy/5 fractions) or…
- Trial name
- OPERA (NCT02505750)
- Testing
- 3D conformal EBRT, Contact X-ray brachytherapy 50 kV, Capecitabine
- Where
- 18 sites in France, Switzerland and 1 more
- Volunteers
- 148 people
- Sponsor
- Centre Antoine Lacassagne
Rectal Neoplasms
Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy With 5-Fluorouracil and Oxaliplatin Versus 5-Fluorouracil Alone in Rectal Cancer
Standard treatment for locally advanced cancer of the rectum is preoperative chemoradiotherapy with 5-Fluorouracil (5-FU) plus 4 cycles of postoperative chemotherapy with 5-FU.
- Trial name
- NCT00349076
- Testing
- 5-FU and oxaliplatin, 5-FU
- Where
- 89 sites in Germany
- Volunteers
- 1,256 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Patient Satisfaction, Quality of Life
Patient Experiences Following Urinary Diversion as Part of Surgery for Advanced and Recurrent Rectal Cancer
The outcomes of patients who undergo radical surgery for locally advanced and recurrent rectal cancer have improved vastly, but there is a lack of emphasis on the quality-of-life outcomes of these patients.
- Conditions
- Patient Satisfaction, Quality of Life, Patient Participation
- Trial name
- Pelvex 3 (NCT04715308)
- Testing
- Urinary diversion
- Where
- Ireland
- Volunteers
- 1,200 people
- Sponsor
- St Vincent's University Hospital, Ireland
Colon Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer
This phase Ib/II trial studies the side effects and best dose of pan fibroblast growth factor receptor (FGFR) kinase inhibitor BGJ398 when given together with fluorouracil, irinotecan hydrochloride and oxaliplatin (combination…
- Conditions
- Colon Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT02575508
- Testing
- Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.